Value
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 2.7 |
| P/S | 8.6 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 3.8 |
| PEG | 8.9 |
| Analyst target | 9.0 |
- ▸Forward P/E: 31.1x
- ▸PEG: 0.68
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
| Pillar | Expectation | Trend |
|---|---|---|
A wide economic moat and a perfect Piotroski financial health score of 9 out of 9 suggest the brand's competitive position is durable, with a balance sheet discipline that limits the risk of operational self-inflicted wounds. Quality breakdown | The Piotroski F-Score remains at or above 8 for the next two annual reporting periods, confirming continued financial health. | →Stable |
| CounterProduct concentration in core scrubwear creates vulnerability — if fashion trends shift or hospital procurement channels consolidate, pricing power could erode quickly and the moat could prove narrower than current scores suggest. | ||
At a forward P/E of 38.7x, the stock is priced for near-perfection in a consumer-facing apparel business — leaving limited room for any growth miss or margin compression without a significant de-rating. Valuation breakdown | If the valuation is justified, revenue growth stays above 25% year over year and operating margins expand over the next four quarters, supporting the multiple. | →Stable |
| CounterA PEG of 0.84 suggests the growth-adjusted price is reasonable; if management sustains 28% growth, the premium multiple can be supported by earnings growing into the price over time. | ||
Revenue is growing 28% year over year and the stock is above its 200-day moving average with volume accumulating on a rising on-balance basis — a constructive setup where business momentum and price momentum are aligned. Momentum breakdown | Revenue growth stays above 20% year over year for the next two fiscal quarters and the stock holds above its 200-day moving average. | →Stable |
| CounterProduct concentration in core scrubwear styles means topline growth is tied to a single product category; any slippage in healthcare market share or brand relevance could rapidly slow the growth engine. | ||
The put/call ratio stands at 2.00 — twice as many open put contracts as calls — and implied volatility is elevated at 85%, signaling that the options market is pricing in substantial downside risk over the coming quarter. Risk breakdown | For this skepticism to resolve, the put/call ratio would need to compress below 1.0 while implied volatility returns toward historical norms. | →Stable |
| CounterElevated put/call ratios can reflect hedging activity by long investors rather than pure bearish positioning, and may resolve quickly if the next earnings print demonstrates continued outperformance. | ||
CounterProduct concentration in core scrubwear creates vulnerability — if fashion trends shift or hospital procurement channels consolidate, pricing power could erode quickly and the moat could prove narrower than current scores suggest.
CounterA PEG of 0.84 suggests the growth-adjusted price is reasonable; if management sustains 28% growth, the premium multiple can be supported by earnings growing into the price over time.
CounterProduct concentration in core scrubwear styles means topline growth is tied to a single product category; any slippage in healthcare market share or brand relevance could rapidly slow the growth engine.
CounterElevated put/call ratios can reflect hedging activity by long investors rather than pure bearish positioning, and may resolve quickly if the next earnings print demonstrates continued outperformance.
Healthy revenue growth and constructive price momentum are supported by a defensible competitive position in healthcare apparel, but a forward P/E of 38.7x and a put/call ratio of 2.00 signal meaningful execution risk and limited room for disappointment.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Component | Sub-score |
|---|---|
| P/E | 2.7 |
| P/S | 8.6 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 3.8 |
| PEG | 8.9 |
| Analyst target | 9.0 |
| Component | Sub-score |
|---|---|
| ROE | 3.3 |
| ROA | 3.3 |
| Gross margin | 9.3 |
| Op margin | 1.1 |
| Net margin | 3.1 |
| Current ratio | 7.6 |
| FCF quality | 5.4 |
| Moat | 7.9 |
| Rule of 40 | 5.5 |
| Piotroski F | 10.0 |
| Component | Sub-score |
|---|---|
| Rev growth | 9.5 |
| EPS growth | 10.0 |
| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 1.4 |
| OBV | 1.0 |
| MA position | 2.2 |
| Volume | 3.9 |
| Component | Sub-score |
|---|---|
| Analyst rating | 6.8 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.2 |
| Component | Sub-score |
|---|---|
| value rank | 0.8 |
| quality rank | 5.7 |
| growth rank | 7.9 |
| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.6 |
| 52w position | 1.4 |
| Component | Sub-score |
|---|---|
| short interest | 2.5 |
| days to cover | 5.4 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.1 |
| beta | 7.0 |
| debt equity | 9.4 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
Maintain position. Not compelling to add more.
L4:PATH_F_HOLDnone
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -43% (>40% off 52w high)
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: ASYMMETRY:3.8>=1.5. Top dim: Growth at 9.8; weakest: Momentum at 2.4. No conviction either direction.
The strongest dimensions are Growth at 9.8, Catalyst at 7.5, and Sentiment at 7.3; the weakest are Momentum at 2.4, Insider at 3.9, and Risk (lower is worse) at 4.4. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 3.75 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifRevenue growth falls below 15% year over year for 2 consecutive quarters.
Trip ifPiotroski F-Score falls below 6 for 2 consecutive annual reporting periods.
Trip ifForward P/E compresses below 20x following a price decline that meaningfully reduces the valuation premium.
Trip ifPut/call ratio falls below 0.80 for 4 consecutive weeks.